Donald Trump can’t close the deal. Peggy Noonan, to

New Post Public Reply Private Reply Replies (1) Message Board
Bhawks
233
Donald Trump can’t close the deal.


Quote:
Peggy Noonan, to whom we owe that observation, has his number: He is soft, weak, whimpering, and petulant. He isn’t smart enough to do the job and isn’t man enough to own up to the fact. For all his gold-plated toilets, he is at heart that middling junior salesman watching Glengarry Glen Ross and thinking to himself: “That’s the man I want to be.”

How many times do you imagine he has stood in front of a mirror trying to project like Alec Baldwin? Unfortunately for the president, it’s Baldwin who does the good imitation of Trump, not the other way around.

Hence the cartoon tough-guy act. Scaramucci’s star didn’t fade when he gave that batty and profane interview in which he reimagined Steve Bannon as a kind of autoerotic yogi. That’s Scaramucci’s best impersonation of the sort of man the president of these United States, God help us, aspires to be. But he isn’t that guy. He isn’t Blake. He’s poor sad old Shelley Levene, who cannot close the deal, who spends his nights whining about the unfairness of it all. So, listen up, Team Trump: “Put that coffee down. Coffee is for closers only.” Got that?



Donald Trump can’t close the deal.

A few years ago in New York, Al Pacino starred in a revival of David Mamet’s Glengarry Glen Ross, and the casting was poignant: In 1992, a much younger and more vigorous Pacino had played the role of hotshot salesman Ricky Roma in the film adaptation of the play; in the Broadway revival, a 72-year-old Pacino played the broken-down has-been Shelley Levene. Glengarry Glen Ross is the Macbeth of real estate, full of great, blistering lines and soliloquies so liberally peppered with profanity that the original cast had nicknamed the show “Death of a F***ing Salesman.”

But a few of those attending the New York revival left disappointed. For a certain type of young man, the star of Glengarry Glen Ross is a character called Blake, played in the film by Alec Baldwin. We know that his name is “Blake” only from the credits; asked his name by one of the other salesmen, he answers: “What’s my name? F*** you. That’s my name.”

In the film, Blake sets things in motion by delivering a motivational speech and announcing a sales competition: “First prize is a Cadillac Eldorado. Second prize? A set of steak knives. Third prize is, you’re fired. Get the picture?” He berates the salesmen in terms both financial — “My watch cost more than your car!” — and sexual. Their problem, in Blake’s telling, isn’t that they’ve had a run of bad luck or bad sales leads — or that the real estate they’re trying to sell is crap — it is that they aren’t real men.

The leads are weak? You’re weak. . . . Your name is “you’re wanting,” and you can’t play the man’s game. You can’t close them? Then tell your wife your troubles, because only one thing counts in this world: Get them to sign on the line which is dotted. Got that, you f***ing f*****s? A few young men waiting to see the show had been quoting Blake’s speech to one another.

For them, and for a number of men who imagine themselves to be hard-hitting competitors (I’ve never met a woman of whom this is true), Blake’s speech is practically a creed. It’s one of those things that some guys memorize.

But Blake does not appear in the play, the scene having been written specifically for the film and specifically for Alec Baldwin, a sop to investors who feared that the film would not be profitable and wanted an additional jolt of star power to enliven it.

That’s some fine irony: Blake’s paean to salesmanship was written to satisfy salesmen who did not quite buy David Mamet’s original pitch. The play is if anything darker and more terrifying without Blake, leaving the poor feckless salesmen at the mercy of a faceless malevolence offstage rather than some regular jerk in a BMW. But a few finance bros went home disappointed that they did not get the chance to sing along, as it were, with their favorite hymn

These guys don’t want to see Alec Baldwin in Glengarry Glen Ross. What they want is to be Blake. They want to swagger, to curse, to insult, and to exercise power over men, exercising power over men being the classical means to the end of exercising power over women, which is of course what this, and nine-tenths of everything else in human affairs, is about.

Blake is a specimen of that famous creature, the “alpha male,” and establishing and advertising one’s alpha creds is an obsession for some sexually unhappy contemporary men. There is a whole weird little ecosystem of websites (some of them very amusing) and pickup-artist manuals offering men tips on how to be more alpha, more dominant, more commanding, a literature that performs roughly the same function in the lives of these men that Cosmopolitan sex tips play in the lives of insecure women.

Of course this advice ends up producing cartoonish, ridiculous behavior. If you’re wondering where Anthony Scaramucci learned to talk and behave like such a Scaramuccia, ask him how many times he’s seen Glengarry Glen Ross.

What’s notable about the advice offered to young men aspiring to be “alpha males” is that it is consistent with the classic salesmanship advice offered by the real-world versions of Blake in a hundred thousand business-inspiration books (Og Mandino’s The Greatest Salesman in the World is the classic of the genre) and self-help tomes, summarized in an old Alcoholics Anonymous slogan: “Fake it ’til you make it.”

For the pick-up artists, the idea is that simply acting in social situations as though one were confident, successful, and naturally masterful is a pretty good substitute for being those things.

Never mind the advice of Cicero (esse quam videri, be rather than seem) or Rush — just go around acting like Blake and people will treat you like Blake.

If that sounds preposterous, remind yourself who the president of the United States of America is. Trump is the political version of a pickup artist, and Republicans — and America — went to bed with him convinced that he was something other than what he is.

Trump inherited his fortune but describes himself as though he were a self-made man. We did not elect Donald Trump; we elected the character he plays on television. He has had a middling career in real estate and a poor one as a hotelier and casino operator but convinced people he is a titan of industry. He has never managed a large, complex corporate enterprise, but he did play an executive on a reality show.

He presents himself as a confident ladies’ man but is so insecure that he invented an imaginary friend to lie to the New York press about his love life and is now married to a woman who is open and blasé about the fact that she married him for his money.

He fixates on certain words (“negotiator”) and certain classes of words (mainly adjectives and adverbs, “bigly,” “major,” “world-class,” “top,” and superlatives), but he isn’t much of a negotiator, manager, or leader. He cannot negotiate a health-care deal among members of a party desperate for one, can’t manage his own factionalized and leak-ridden White House, and cannot lead a political movement that aspires to anything greater than the service of his own pathetic vanity.

He wants to be John Wayne, but what he is is “Woody Allen without the humor.”

Peggy Noonan, to whom we owe that observation, has his number: He is soft, weak, whimpering, and petulant. He isn’t smart enough to do the job and isn’t man enough to own up to the fact. For all his gold-plated toilets, he is at heart that middling junior salesman watching Glengarry Glen Ross and thinking to himself: “That’s the man I want to be.” How many times do you imagine he has stood in front of a mirror trying to project like Alec Baldwin? Unfortunately for the president, it’s Baldwin who does the good imitation of Trump, not the other way around.

Hence the cartoon tough-guy act. Scaramucci’s star didn’t fade when he gave that batty and profane interview in which he reimagined Steve Bannon as a kind of autoerotic yogi. That’s Scaramucci’s best impersonation of the sort of man the president of these United States, God help us, aspires to be. But he isn’t that guy. He isn’t Blake.

He’s poor sad old Shelley Levene, who cannot close the deal, who spends his nights whining about the unfairness of it all. So, listen up, Team Trump: “Put that coffee down. Coffee is for closers only.” Got that?

Read more at:

http://www.nationalreview.com/article/449988/...g-salesman?
utm_source=PANTHEON_STRIPPED&utm_medium=PANTHEON_STRIPPED&utm_campaign=PANTHEON_STRIPPED?utm_source=PANTHEON_STRIPPED&utm_medium=PANTHEON_STRIPPED&utm_campaign=PANTHEON_STRIPPED

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurra Markets Wins 'Most Transparent Broker' Award 2026

Updated Category News Views 1

Spotlight on Transparency in Trading Alright, so Aurra Markets snagged the 'Most Transparent Broker' award at the Money Expo in Mumbai this year. From the greasy streets of trading floors to the polished halls of Jio World Convention Centre, transparency is one of those golden words you hear tossed around, but like finding a needle in a haystack, it’s not always easy to...

Continue Reading
LITEON Bets Big on Liquid Cooling with DCX Stake

Updated Category News Views 2

Liquid Cooling: The AI Data Center Game Changer Alright, here's a twist in the tech saga that even a crusty old trader like me finds intriguing. LITEON (2301.TW) has made a bold move investing in DCX Liquid Cooling Systems with a $176 million deal for 25% equity. We're talking about liquid cooling here—it's the magic ingredient when your AI and HPC data centers start...

Continue Reading
Ares Management Heads to Barclays Conference Spotlight

Updated Category News Views 4

All Eyes on Ares – From the Trading Floor to Barclays Nothing like the crisp snap of traders' attention when big players like Ares Management Corporation (NYSE:ARES) are set to spill some beans at a fancy conference. Come September 16, 2026, Ares' head honcho, Michael Arougheti, will be hitting the stage at the Barclays Global Financial Services Conference. It’s the...

Continue Reading
Curaleaf Eyes Growth: Conference Signals Opportunities

Updated Category News Views 0

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Continue Reading
Navimow's H5 Pro Mower Marries Tech with Nature Care

Updated Category News Views 2

Garden Tech Reinvented: Enter the H5 Pro Mower Welcome to the 21st-century garden, where robotic ingenuity meets a genuine regard for nature. Folks, the Navimow H5 Pro just rolled onto the scene and it’s tearing up the old playbook of garden maintenance. It’s like blending Silicon Valley tech with Jane Goodall’s wildlife sensibilities. We're talking zero-edge...

Continue Reading
Joseph Spine Opens New Regenerative Therapy Center

Updated Category News Views 1

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Continue Reading
Eosera Defies Odds with Texas-Made Ear Care Dominance

Updated Category News Views 1

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Continue Reading
Perspecta's Study Reveals Troubling Data Accuracy Gaps

Updated Category News Views 1

Data Accuracy in Healthcare: A Persistent Problem Just when you think data's about numbers and cold, hard facts, healthcare jolts you awake. Perspecta's fresh insights onto provider data accuracy aren't just a snooze fest of statistics but a genuine wake-up call. This report peels open a can of worms some might prefer to ignore. With only half of provider data accurate,...

Continue Reading
Nasdaq Flashes Warning Signs for Scage Future's Compliance

Updated Category News Views 2

Two Strikes from Nasdaq: A Wake-Up Call? Scage Future's getting a double-shot of reality from Nasdaq after slipping under crucial thresholds. Here's the score: Scage's been dinged on their Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS). Over a stretch from mid-July to late August, these benchmarks floundered below the line. The...

Continue Reading
Alcatraz AI: A Silent Titan in Data Center Security

Updated Category News Views 0

Why Alcatraz AI is the Security of Choice Forget flashy press releases and splashy marketing campaigns. Alcatraz AI, a company operating out of the hustle and bustle of Cupertino, has managed to quietly dominate a key sector without many folks being the wiser. What's their claim to fame, you ask? They're the chosen gatekeepers for over half of the hyperscale data centers...

Continue Reading

Top 5 Most Recently Viewed Articles

QuinStreet Achieves Unprecedented Fiscal Growth

Updated Category News Views 46

QuinStreet Reports Exceptional Financial Performance QuinStreet, Inc. (NASDAQ: QNST), recognized for its innovative performance marketing solutions, recently unveiled astounding financial results, showcasing a robust increase that has positioned the company as a leader in its sector. Record Revenue Growth For the recent fiscal quarter, QuinStreet reported an impressive...

Continue Reading
Senti Bio to Showcase Innovative Gene Therapies at SEED 2025

Updated Category News Views 185

Senti Bio to Showcase Innovative Gene Therapies at SEED 2025 Senti Biosciences, Inc. (Nasdaq: SNTI), a pioneering clinical-stage biotechnology company, is set to present at the highly anticipated 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference. This premier event, taking place from June 23 to June 26, 2025, is an essential gathering for...

Continue Reading
Monthly Distributions Announced by Premium Income Corporation

Updated Category News Views 135

Premium Income Corporation Monthly Distribution Details Premium Income Corporation has declared an update regarding its monthly distributions which will be beneficial for its shareholders. This announcement highlights the allocation of payments to different share classes, ensuring that investors are well-informed about their upcoming earnings. Distribution Schedule The...

Continue Reading
Why Branded Condominiums in Miami Are a Smart Investment Option

Updated Category News Views 235

Branded Condominiums: A Growing Trend in Miami In the competitive world of real estate, luxury developers are increasingly tapping into the appeal of branded condominiums to attract high-net-worth clients. These upscale residential projects are no longer just about prime locations; they incorporate well-known retail and lifestyle brands to appeal to discerning buyers....

Continue Reading
Investors Anticipate Earnings Update from CBAK Energy Tech

Updated Category News Views 79

Insights Into CBAK Energy Tech's Upcoming Earnings Report CBAK Energy Tech (NASDAQ: CBAT) is gearing up to unveil its quarterly earnings report, generating buzz among investors and market watchers. This report, anticipated soon, holds significant implications for the company's future outlook. Expectations for Earnings Performance Analysts are predicting an earnings per...

Continue Reading